e5bfa150-ea77-423d-b26c-62f9b241e2b7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68.3367556468173
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- E2F_TARGETS+0.510
- MYC_TARGETS_V1+0.460
- DNA_REPAIR+0.400
- OXIDATIVE_PHOSPHORYLATION+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- G2M_CHECKPOINT+0.300
- UV_RESPONSE_UP+0.240
- PEROXISOME+0.220
- NOTCH_SIGNALING+0.170
Top 10 suppressed
- ANDROGEN_RESPONSE-0.370
- HEDGEHOG_SIGNALING-0.360
- TGF_BETA_SIGNALING-0.360
- PROTEIN_SECRETION-0.330
- HEME_METABOLISM-0.300
- APICAL_SURFACE-0.260
- MITOTIC_SPINDLE-0.260
- UV_RESPONSE_DN-0.250
- APICAL_JUNCTION-0.220
- INTERFERON_ALPHA_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.847 |
| 2 | d7856acd-b750-4d86-988f-371045e74768 | — | — | 0.844 |
| 3 | FFAA0A2D-49B7-4491-9B22-C82CCF1501D0 | — | — | 0.836 |
| 4 | TCGA-A2-A3XU-01A-12R-A22U-07 | — | E | 0.816 |
| 5 | 13CA931D-C2D3-485E-9B18-A21B624C602E | — | — | 0.809 |
| 6 | SRR8518329 | — | E | 0.806 |
| 7 | SRR8942959 | — | — | 0.792 |
| 8 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.789 |
| 9 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.779 |
| 10 | TCGA-AN-A04C-01A-21R-A034-07 | — | C | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |